In vitro activity of the new fluoroketolide solithromycin (CEM-101) against a large collection of clinical Neisseria gonorrhoeae isolates and international reference strains, including those with high-level antimicrobial resistance: Potential treatment option for gonorrhea?

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 5, 2012, Pages 2739-2742

  Golparian, Daniel ^a   Fernandes, Prabhavathi ^b   Ohnishi, Makoto ^c   Jensen, Jörgen S ^d   Unemo, Magnus ^a  

^a ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^b Cempra Pharmaceuticals Inc   (United States)

^c NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^d STATENS SERUM INSTITUT   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; AZITHROMYCIN; CEFIXIME; CEFTRIAXONE; CEPHALOSPORIN; CIPROFLOXACIN; ERYTHROMYCIN; SOLITHROMYCIN; SPECTINOMYCIN; TELITHROMYCIN; TETRACYCLINE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; DRUG EFFICACY; GONORRHEA; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NEISSERIA GONORRHOEAE; NONHUMAN; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; CEPHALOSPORIN RESISTANCE; CEPHALOSPORINS; CULTURE MEDIA; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ERYTHROMYCIN; HUMANS; MACROLIDES; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; NEISSERIA GONORRHOEAE; TRIAZOLES;

EID: 84860176932     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00036-12     Document Type: Article

References (40)

1. Barry PM, Klausner JD. 2009. The use of cephalosporins for gonorrhea: the impending problem of resistance. Expert Opin. Pharmacother. 10:555-577.
2. Biedenbach DJ, Castanheira M, Jones RN. 2010. Determination of CEM-101 activity tested against clinical isolates of Neisseria meningitidis from a worldwide collection. Antimicrob. Agents Chemother. 54:4009-4011.
3. Bignell C, Fitzgerald M, Guideline Development Group. 2011. UK national guideline for the management of gonorrhoea in adults, 2011. Int. J. STD AIDS 22:541-547.
4. Centers for Disease Control and Prevention (CDC). 2011. Cephalosporin susceptibility among Neisseria gonorrhoeae isolates - United States, 2000-2010. MMWR Morb. Mortal. Wkly. Rep. 60:873-877.
5. Chisholm SA, Dave J, Ison CA. 2010. High-level azithromycin resistance occurs in Neisseria gonorrhoeae as a result of a single point mutation in the 23S rRNA genes. Antimicrob. Agents Chemother. 54:3812-3816.
6. Chisholm SA, et al. 2009. Emergence of high-level azithromycin resistance in Neisseria gonorrhoeae in England and Wales. J. Antimicrob. Chemother. 64:353-358.
7. Clinical and Laboratory Standards Institute. 2011. Performance standards for antimicrobial susceptibility testing, 21st informational supplement, CLSI document M100-S21. CLSI, Wayne, PA.
8. Cole MJ, et al. 2011. The European gonococcal antimicrobial surveillance programme, 2009. Euro Surveill. 16(42):pii=19995.
9. Deguchi T, et al. 2003. Treatment of uncomplicated gonococcal urethritis by double-dosing of 200 mg cefixime at a 6-h interval. J. Infect. Chemother. 9:35-39. (Pubitemid 36504368)
10. Farrell DJ, Castanheira M, Sader HS, Jones RN. 2010. The in vitro evaluation of solithromycin (CEM-101) against pathogens isolated in the United States and Europe (2009). J. Infect. 61:476-483.
11. Galarza PG, et al. 2010. New mutation in 23S rRNA gene associated with high level of azithromycin resistance in Neisseria gonorrhoeae. Antimicrob. Agents Chemother. 54:1652-1653.
12. Golparian D, Hellmark B, Fredlund H, Unemo M. 2010. Emergence, spread and characteristics of Neisseria gonorrhoeae isolates with in vitro decreased susceptibility and resistance to extended-spectrum cephalosporins in Sweden. Sex. Transm. Infect. 86:454-460.
13. Ison CA, Hussey J, Sankar KN, Evans J, Alexander S. 2011. Gonorrhoea treatment failures to cefixime and azithromycin in England, 2010. Euro Surveill. 16(14):pii=19833.
14. Katz AR, et al. 2012. Neisseria gonorrhoeae with high-level resistance to azithromycin: case report of the first isolate identified in the United States. Clin. Infect. Dis. 54:841-843.
15. Kirkcaldy RD, Ballard RC, Dowell D. 2011. Gonococcal resistance: are cephalosporins next? Curr. Infect. Dis. Rep. 13:196-204.
16. Kubanova A, et al. 2010. The Russian gonococcal antimicrobial susceptibility programme (RU-GASP) - national resistance prevalence in 2007 and 2008, and trends during 2005-2008. Euro Surveill. 15(14):pii=19533.
17. Lemaire S, Van Bambeke F, Tulkens PM. 2009. Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria mono-cytogenes, and Legionella pneumophila in human THP-1 macrophages. Antimicrob. Agents Chemother. 53:3734-3743.
18. Lewis DA. 2010. The gonococcus fights back: is this time a knock out? Sex. Transm. Infect. 86:415-421.
19. Martin I, et al. 2011. Trends in antimicrobial resistance in Neisseria gonorrhoeae isolated in Canada: 2000-2009. Sex. Transm. Dis. 38:892-898.
20. McGhee P, et al. 2010. In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. Antimicrob. Agents Chemother. 54:230-238.
21. Ohnishi M, et al. 2011. Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob. Agents Chemother. 55:3538-3545.
22. Palmer HM, Young H, Winter A, Dave J. 2008. Emergence and spread of azithromycin-resistant Neisseria gonorrhoeae in Scotland. J. Antimicrob. Chemother. 62:490-494.
23. Putnam SD, Castanheira M, Moet GJ, Farrell DJ, Jones RN. 2010. CEM-101, a novel fluoroketolide: antimicrobial activity against a diverse collection of Gram-positive and Gram-negative bacteria. Diagn. Microbiol. Infect. Dis. 66:393-401.
24. Roblin PM, Kohlhoff SA, Parker C, Hammerschlag MR. 2010. In vitro activity of CEM-101, a new fluoroketolide antibiotic, against Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae. Antimicrob. Agents Chemother. 54:1358-1359.
25. Ross DB. 2007. The FDA and the case of Ketek. N. Engl. J. Med. 356:1601-1604. (Pubitemid 46631668)
26. Starnino S, Stefanelli P, Neisseria gonorrhoeae Italian Study Group. 2009. Azithromycin-resistant Neisseria gonorrhoeae strains recently isolated in Italy. J. Antimicrob. Chemother. 63:1200-1204.
27. Still JG, et al. 2011. Pharmacokinetics of solithromycin (CEM-101) after single or multiple oral doses and effects of food on single-dose bioavailability in healthy adult subjects. Antimicrob. Agents Chemother. 55:1997-2003.
28. Tanaka M, et al. 2011. Antibiotic-resistant phenotypes and genotypes of Neisseria gonorrhoeae isolates in Japan: identification of strain clusters with multidrug-resistant phenotypes. Sex. Transm. Dis. 38:871-875.
29. Tapsall JW, Ndowa F, Lewis DA, Unemo M. 2009. Meeting the public health challenge of multidrug-and extensively drug-resistant Neisseria gonorrhoeae. Expert Rev. Anti Infect. Ther. 7:821-834.
30. Tapsall J, et al. 2009. Two cases of failed ceftriaxone treatment in pharyngeal gonorrhoea verified by molecular microbiological methods. J. Med. Microbiol. 58:683-687.
31. Unemo M, Fasth O, Fredlund H, Limnios A, Tapsall J. 2009. Phenotypic and genetic characterization of the 2008 WHO Neisseria gonorrhoeae reference strain panel intended for global quality assurance and quality control of gonococcal antimicrobial resistance surveillance for public health purposes. J. Antimicrob. Chemother. 63:1142-1151.
32. Unemo M, Golparian D, Hestner A. 2011. Ceftriaxone treatment failure of pharyngeal gonorrhoea verified by international recommendations, Sweden, July 2010. Euro Surveill. 16(6):pii=19792.
33. Unemo M, et al. 2012. High-level cefixime-and ceftriaxone-resistant N. gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob. Agents Chemother. 56:1273-1280.
34. Unemo M, Golparian D, Stary A, Eigentler A. 2011. First Neisseria gonorrhoeae strain with resistance to cefixime causing gonorrhoea treatment failure in Austria, 2011. Euro Surveill. 16(43):pii=19998.
35. Unemo M, Golparian D, Syversen G, Vestrheim DF, Moi H. 2010. Two cases of verified clinical failures using internationally recommended firstline cefixime for gonorrhoea treatment, Norway, 2010. Euro Surveill. 15(47):pii=19721.
36. Unemo M, Shafer WM. 2011. Antibiotic resistance in Neisseria gonorrhoeae: origin, evolution, and lessons learned for the future. Ann. N. Y. Acad. Sci. 1230:E19-E28.
37. Waites KB, Crabb DM, Duffy LB. 2009. Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101. Antimicrob. Agents Chemother. 53:2139-2141.
38. Woosley LN, Castanheira M, Jones RN. 2010. CEM-101 activity against Gram-positive organisms. Antimicrob. Agents Chemother. 54:2182-2187.
39. Workowski KA, Berman S, Centers for Disease Control and Prevention (CDC). 2010. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recommend. Rep. 59(RR-12):1-110.
40. Yokoi S, et al. 2007. Threat to cefixime treatment of gonorrhea. Emerg. Infect. Dis. 13:1275-1277.